Last updated on February 2018

Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children


Brief description of study

A two-arm, Phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of current standard antiretroviral therapy compared to once daily integrase inhibitor administered with darunavir/ritonavir (DRV/r) in HIV-1 infected, virologically suppressed paediatric participants.

Detailed Study Description

A two arm parallel group, non-inferiority, open-label, multi-centre, randomised controlled trial.

Clinical Study Identifier: NCT02383108

Find a site near you

Start Over